]>
IRCT20221016056203N1 IRCT 2022-11-19 Tehran University of Medical Sciences studying the effect of botox on hormonal female hair loss A comparative study of the results of using botulinum toxin by different doses in women suffering from androgenic alopecia . 2022-11-22 anticipated 63 Complete https://irct.ir/trial/66404 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomized assignment of individuals to treatment and controls groups. simple with sealed envelopes containing the material , Blinding description: Double blinded The patient receives the injection substance (intervention or control group) in sealed envelopes that are coded. Coding is done by one of the collaborators of the project and the evaluator and the patient are blinded. 2-3 androgenetic alopecia. Intervention 1: Control group: using minoxidil solution 5% with normal saline injection. Intervention 2: Intervention group: using minoxidil 5% solution with the injection of 100 units botulinum toxin (Masport). Intervention 3: Intervention group: using minoxidil 5% solution with the injection of 200 units botulinum toxin (Masport). No - There is not a plan to make this available Justification or reason for not sharing IPD is Individual information about the disease will be confidential and will be shared in general about the effect of the treatment on all patients
public Hawraa Taleb
No 82 , Behzad sedakat intersection ,Zhiyan Panah street
Tehran Iran (Islamic Republic of) 1111111111 +98 922 231 3954 hawraa-taleb@outlook.com Tehran University of Medical Sciences scientific Safoura Shakoei Nejad
No 82 , Behzad sedakat intersection ,Zhiyan Panah street .
Tehran Iran (Islamic Republic of) 111111111 +98 922 231 3954 hawraa-taleb@outlook.com Tehran University of Medical Sciences Iran (Islamic Republic of) Patients with grade 2/4/3 based on SINCLAIR SCALE for disease severity having the ability for regular visits Not receiving previous treatment in the last three months age between 18-55 not having contraindication for minoxidil 5% and botulinum toxin 18 years 55 years Female Having needle phobia Having alopecia areata and another hair diseases(LPP) Having neuromuscular disease Previous use of corticosteroids or immunosuppressive drugrs in the last 3 months Having localized infection Having internal systemic and skin disease or localized dermatosis. Patients with a history of bleeding diseases or under treatment with anticoagulants Previous family or personal history of keloid Having koebner phenomenon Having symptoms of hyperandrogenism and in need for systemic drugs pregnancy and lactation Another treatments in less than 3 months. L64 Androgenic alopecia Treatment - Drugs Treatment - Drugs Treatment - Drugs Control group: using minoxidil solution 5% with normal saline injection Intervention group: using minoxidil 5% solution with the injection of 100 units botulinum toxin (Masport) Intervention group: using minoxidil 5% solution with the injection of 200 units botulinum toxin (Masport). Hair volume and density in qualitative and quantitative way. Timepoint: 3 and 6 months after starting treatment. Method of measurement: photography - photo finder - dermoscopy -self assessment. Masoondarou pharmaceutical Company MDPC Tehran University of Medical Sciences Masoondarou pharmaceutical Company MDPC Approved 2022-10-22 Ethics committee of Tehran University of Medical Sciences No 82 , Behzad sedakat intersection ,Zhiyan Panah street . Tehran Tehran Iran (Islamic Republic of)